Macleod ivor
Known title: Chief Financial OfficerCIK: 0001800734
Associated companies
Transaction History
| SCYX | ▲ Buy | Grant | 129,833 | $0 | 1/29/2026 | View on chart |
| SCYX | ▲ Buy | Grant | 92,511 | $0 | 1/23/2025 | View on chart |
| SCYX | ▲ Buy | Grant | 143,675 | $0 | 1/26/2024 | View on chart |
| SCYX | ▲ Buy | Grant | 15,000 | $0 | 10/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
SCYNEXIS Wins $214M BARDA Contract for SCY-247
SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.
SCYNEXIS Wins $214M BARDA Contract for SCY-247. SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.